Results 81 to 90 of about 4,368 (233)

Improved AcroQoL scores in acromegaly after sagittal split ramus osteotomy with Le Fort I osteotomy

Endocrinology, Diabetes & Metabolism Case Reports, 2021
Acromegaly is associated with a low quality of life (QoL), which is partially attributable to appearance. However, appearance changes are only partially reversible with treatments of growth hormone excess. This case study describes a 41-year-old Japanese
Tomomi Taguchi, Sachiko Kimizuka, Koji Takano   +2 more
doaj   +1 more source

Early Lung Function Abnormalities in Acromegaly. [PDF]

, 2015
BACKGROUND: Acromegaly is an insidious disorder caused by a pituitary growth hormone (GH)-secreting adenoma resulting in high circulating levels of GH and insulin-like growth factor I (IGF-I). Respiratory disorders are common complications in acromegaly,
A Giustina, A Troyer De, A. Benfante, A. Ciresi, American Thoracic Society, B Trotman-Dickenson, BD Harrison, C. Giordano, F. Cannizzaro, G Burri, GB Camilo, HM O’Brodovich, JS Brody, LA Frohman, M. Bellia, N. Scichilone, NJ Murrant, NM Siafakas, P Attal, PJ Trainer, PM Donnelly, R Pellegrino, S Melmed, S Melmed, V. Bellia   +24 more
core   +1 more source

Acromegaly management in the Nordic countries: A Delphi consensus survey

Clinical Endocrinology, Volume 101, Issue 3, Page 263-273, September 2024.
Abstract Objective Acromegaly is associated with increased morbidity and mortality if left untreated. The therapeutic options include surgery, medical treatment, and radiotherapy. Several guidelines and recommendations on treatment algorithms and follow‐up exist. However, not all recommendations are strictly evidence‐based. To evaluate consensus on the
Mai C. Arlien‐Søborg, Jakob Dal, Ansgar Heck, Kirstine Stochholm, Eigil Husted, Claus Larsen Feltoft, Åse Krogh Rasmussen, Ulla Feldt‐Rasmussen, Mikkel Andreassen, Marianne Christina Klose, Torben Leo Nielsen, Marianne Skovsager Andersen, Louise Lehmann Christensen, Jesper Krogh, Anne Jarlov, Jens Bollerslev, Ingrid Nermoen, Marianne Oksnes, Per Dahlqvist, Tommy Olsson, Katarina Berinder, Charlotte Hoybye, Maria Petersson, Anna‐karin Akerman, Jeanette Wahlberg, Bertil Ekman, Britt Eden Engstrom, Gudmundur Johannsson, Oskar Ragnarsson, Daniel Olsson, Helga Ágústa Sigurjónsdóttir, Stine Lyngvi Fougner, Niina Matikainen, Satu Vehkavaara, Saara Metso, Pia Jaatinen, Päivi Hämäläinen, Reeta Rintamäki, Iina Yliaska, Heidi Immonen, Sari Mäkimattila, Henna Cederberg‐Tamminen, Marianna Viukari, Pasi Nevalainen, Pirjo Nuutila, Camilla Schalin‐Jäntti, Pia Burman, Jens Otto Lunde Jørgensen   +47 more
wiley   +1 more source

Pituitary hormones are specifically expressed in trigeminal sensory neurons and contribute to pain responses in the trigeminal system

Scientific Reports, 2021
Trigeminal (TG), dorsal root (DRG), and nodose/jugular (NG/JG) ganglia each possess specialized and distinct functions. We used RNA sequencing of two-cycle sorted Pirt-positive neurons to identify genes exclusively expressing in L3–L5 DRG, T10-L1 DRG, NG/
Anahit H. Hovhannisyan, Hyeonwi Son, Jennifer Mecklenburg, Priscilla Ann Barba-Escobedo, Meilinn Tram, Ruben Gomez, John Shannonhouse, Yi Zou, Korri Weldon, Shivani Ruparel, Zhao Lai, Alexei V. Tumanov, Yu Shin Kim, Armen N. Akopian   +13 more
doaj   +1 more source

Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations [PDF]

, 2015
Objective: The studies that have extensively evaluated the relation between adipokines and metabolic parameters in acromegaly treatment are quite discordant. We aimed to evaluate and correlate a set of selected adipokines, known to have a metabolic role,
Amato, M., Ciresi, A., Giordano, C., Pizzolanti, G.   +3 more
core   +1 more source

Identification of common mechanisms and biomarkers of atrial fibrillation and heart failure based on machine learning

ESC Heart Failure, Volume 11, Issue 4, Page 2323-2333, August 2024.
Abstract Aims Atrial fibrillation (AF) is the most common arrhythmia. Heart failure (HF) is a disease caused by heart dysfunction. The prevalence of AF and HF were progressively increasing over time. The co‐existence of AF and HF presents a significant therapeutic challenge.
Zhijun Zhang, Jianying Ding, Xiaolong Mi, Yuanyuan Lin, Xinjian Li, Jun Lian, Jinwen Liu, Lijuan Qu, Bingye Zhao, Xuewen Li   +9 more
wiley   +1 more source

Efficacy of combined treatment with pasireotide, pegvisomant and cabergoline in an acromegalic patient resistant to other treatments: a case report

BMC Endocrine Disorders, 2018
Background The approach to acromegalic patients with persistent acromegaly after surgery and inadequate response to first-generation somatostatin receptor ligands (SRLs) should be strictly tailored.
A. Ciresi, S. Radellini, V. Guarnotta, C. Giordano   +3 more
doaj   +1 more source

Treatment adherence to pegvisomant (somavert®) in Spain: PEGASO study [PDF]

, 2017
This is a pre-copyedited, author-produced version of an article accepted for publication in Endocrine Reviews following peer review.
Aller, J., Cordido, Fernando, Cámara, Rosa, García-Arnés, Juan Antonio, Martín, Víctor, Mir, Nuria, Sánchez-Cenizo, Laura, Venegas, Eva   +7 more
core  

Lanreotide extended-release aqueous-gel formulation, injected by patient, partner or healthcare provider in patients with acromegaly in the United States: 1-year data from the SODA registry [PDF]

, 2014
Lanreotide depot (LD; commercial name Somatuline® Depot) is an injectable, extended-release formulation of the synthetic somatostatin analog (SSA) lanreotide.
Gordon, Murray B., Lomax, Kathleen G., Molitch, Mark, Salvatori, Roberto, Woodmansee, Whitney W.   +4 more
core   +1 more source

Pegvisomant as Monotherapy or Combination Therapy in Somatostatin Refractory Acromegaly

, 2021
Background: Pegvisomant, a growth hormone antagonist, has been widely used as monotherapy or combination therapy with somatostatin (SST) analogs and/or dopamine agonists in acromegaly poorly controlled by SST analogs.
Dawid Hordejuk, E. Laws, U. Kaiser, L. Min   +3 more
semanticscholar   +1 more source